Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Synthelabo Tirapazamine NDA Expected In 2003; ADSs Traded On NYSE

Executive Summary

Sanofi-Synthelabo expects to file a tirapazamine NDA in late 2003 for the treatment of non-small cell lung cancer, the company said in a 1registration statement filed with the Securities & Exchange Commission

You may also be interested in...



From The Quarterly Conference Calls....

Advair for COPD: GSK hopes to receive approval of Advair (fluticasone/salmeterol) for chronic obstructive pulmonary disease in "a few months," CEO J.P. Garnier tells April 24 conference call. Although an FDA advisory committee "was unabashedly in favor" of the new indication, the agency "asked us for some data and we have now supplied the data.... I don't expect this to come to a fast resolution." FDA approved only the NDA for salmeterol (Serevent) for the COPD claim (1"The Pink Sheet" April 1, p. 27)....Off-label use likely: While the Advair COPD indication has hit a snag at FDA, "there is use in the medical community," Garnier notes. "This is not encouraged. It just happens with specialists who have experience with Advair in COPD. We're getting good reports. We're trying to manage this as best we can"...

Organon/Sanofi Arixtra Late January Launch Will Be Supported By 240 Reps

Organon and Sanofi-Synthelabo will launch the injectable antithrombotic Arixtra with 240 sales reps in late January

Eloxatine Progression-Free Survival Data Not Enough For Colorectal Use

Studies showing an overall survival advantage for Sanofi-Synthelabo's Eloxatine over 5-FU-based chemotherapy would be needed for approval of the agent as first-line therapy for colorectal cancer, FDA's Oncologic Drugs Advisory Committee found March 16.

Related Content

UsernamePublicRestriction

Register

PS040135

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel